



**SHUKRA**  
PHARMACEUTICALS LTD.

15<sup>th</sup> September, 2020

To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai.

**Scrip Code: 524632**

Dear Sir/Madam,

**SUB: - OUTCOME OF BOARD MEETING**

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 15<sup>th</sup> September, 2020 at 02.00 p.m. and concluded at 07.20 p.m.:-

1. Considered, adopted and approved Unaudited Financial Results for the quarter ended on 30<sup>th</sup> June, 2020.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited

  
Arpita Shah  
Company Secretary &  
Compliance officer



**CIN : L24231GJ1993PLC019079**



**The Limited Review Report**

**Review Report to Board of Directors  
Shukra Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of Shukra Pharmaceuticals Limited for the quarter ended 30<sup>th</sup> June, 2020. This statement is responsibilities of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and Analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place: Ahmedabad  
Date: 15/09/2020**



**For, B J Trivedi & Associates,  
Chartered Accountants  
FRN 111042W**

  
**Bharat Trivedi  
Proprietor  
M. No. 039595  
UDIN: 20039595AAAADL2349**



# SHUKRA

PHARMACEUTICALS LTD.

PART I		(Rs. in Lakhs)			
Statement of Standalone Unaudited Results for the Quarter Ended 30/06/2020					
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous year ended	
	(30/06/2020)	(31/03/2020)	(30/06/2019)	(31/03/2020)	
(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
<b>I Revenue from Operation</b>	110.89	403.58	104.34	1184.60	
<b>II Other income</b>	13.95	0.71	0.00	0.97	
<b>III Total Revenue (I + II)</b>	124.84	404.29	104.34	1185.57	
<b>IV Expenses</b>					
(a) Cost of materials consumed	35.21	25.46	15.22	332.82	
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(44.14)	20.61	(8.04)	(25.90)	
(d) Employee benefits expense	58.02	138.92	71.17	440.03	
(e) Finance Cost	0.02	0.14	0.07	0.21	
(f) Depreciation and amortisation expense	36.21	62.07	15.00	147.82	
(g) Other expenses	37.65	212.84	10.65	283.61	
<b>Total expenses</b>	122.97	460.04	104.07	1178.59	
<b>V Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)</b>	1.87	(55.75)	0.27	6.98	
<b>VI Exceptional items</b>	0.00	0.20	0.00	0.20	
<b>VII Profit / (Loss) before extraordinary items and tax (V - VI)</b>	1.87	(55.95)	0.27	6.78	
<b>VIII Extraordinary items</b>	0.00	0.00	0.00	10.30	
<b>IX Profit before tax (VII- VIII)</b>	1.87	(55.95)	0.27	17.08	
<b>X Tax expense - Provision for taxation</b>	0.00	(16.79)	0.00	13.52	
<b>XI Net Profit / (Loss) for the period (IX-X)</b>	1.87	(39.16)	0.27	3.56	
<b>XII Other Comprehensive Income</b>	0.00	0.00	0.00	0.00	
Items that will not be reclassified to Profit or Loss: Remeasurement of defined benefits plans (net of tax)					
<b>XIII Total Comprehensive Income (after tax) for the period (9+10)</b>	1.87	(39.16)	0.27	3.56	
<b>XIV Paid up Equity Share Capital (Face value of Re. 10/- each)</b>	156.57	156.57	156.57	156.57	
<b>XV Other Equity excluding revaluation reserve</b>	1401.01	1361.85	1401.01	1391.73	



CIN : L24231GJ1993PLC019079





# SHUKRA

PHARMACEUTICALS LTD.

QVI Earnings per equity share:				
(1) Basic	0.12	(2.50)	0.02	0.23
(2) Diluted	0.12	(2.50)	0.02	0.23

**NOTES:**

1. The above Unaudited Standalone Financial of the company for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and there after approved by the Board of Directors of the Company at their Meeting held on 15th September, 2020. The statutory auditors have carried out a limited
2. The Unaudited Standalone Financial Results of the Company for the quarter ended on June 30,
3. The Company has not calculated the deferred tax liability as the company has not provided depreciation for the Quarter.
4. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
5. The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015.
6. The Company is operating in single segment, so above results are for single segment only.
7. The COVID-19 pandemic has disrupted business due to lockdown and other emergency measures imposed by the Government. The operations of the Company were impacted, due to shutdown of plants and offices following nationwide lockdown. The Company has evaluated the impact of this pandemic on its business operation, liquidity, assets and financial position and based on management's review of current indicator and economic conditions. However, the impact assessment

Date: 15.09.2020

Place: Ahmedabad

For and on behalf of the Board of Directors

Dakshesh Shah

Managing Director

DIN - 00561666

**CIN : L24231GJ1993PLC019079**